Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGE NASDAQ:RNA NASDAQ:RVMD NASDAQ:RYTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$36.35+0.9%$39.67$26.20▼$63.50$1.66B1.43567,350 shs484,772 shsRNAAvidity Biosciences$44.66+0.7%$35.33$21.51▼$56.00$5.70B0.953.90 million shs1.22 million shsRVMDRevolution Medicines$36.48+0.9%$37.64$29.17▼$62.40$6.76B1.161.90 million shs1.96 million shsRYTMRhythm Pharmaceuticals$101.68+3.0%$81.14$43.57▼$101.74$6.56B2.38552,947 shs682,917 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics-1.07%-3.62%-7.90%-10.75%-26.47%RNAAvidity Biosciences+0.73%-4.28%+30.34%+43.91%-1.18%RVMDRevolution Medicines-1.04%+0.32%-5.88%-6.80%-16.59%RYTMRhythm Pharmaceuticals+1.55%+0.86%+11.36%+59.17%+116.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPGEApogee Therapeutics3.5417 of 5 stars4.43.00.00.01.64.20.0RNAAvidity Biosciences3.1363 of 5 stars4.52.00.00.03.90.80.0RVMDRevolution Medicines4.289 of 5 stars4.51.00.04.72.81.70.0RYTMRhythm Pharmaceuticals3.7345 of 5 stars2.53.00.04.33.20.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGEApogee Therapeutics 2.86Moderate Buy$99.00172.35% UpsideRNAAvidity Biosciences 3.06Buy$67.0050.02% UpsideRVMDRevolution Medicines 3.00Buy$69.9291.68% UpsideRYTMRhythm Pharmaceuticals 3.07Buy$101.57-0.11% DownsideCurrent Analyst Ratings BreakdownLatest APGE, RVMD, RYTM, and RNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025RVMDRevolution MedicinesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$75.008/18/2025RVMDRevolution MedicinesLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$80.008/15/2025RVMDRevolution MedicinesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$67.008/14/2025APGEApogee TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/11/2025APGEApogee TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$90.008/8/2025RNAAvidity BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$70.00 ➝ $75.008/8/2025RNAAvidity BiosciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$59.00 ➝ $62.008/8/2025RNAAvidity BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.008/7/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$57.00 ➝ $56.008/7/2025RYTMRhythm PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$80.00 ➝ $100.008/6/2025RYTMRhythm PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$119.00 ➝ $120.00(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGEApogee TherapeuticsN/AN/AN/AN/A$13.43 per shareN/ARNAAvidity Biosciences$10.73M535.52N/AN/A$9.27 per share4.82RVMDRevolution Medicines$11.58M588.88N/AN/A$9.98 per share3.66RYTMRhythm Pharmaceuticals$130.13M51.90N/AN/A($0.18) per share-564.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGEApogee Therapeutics-$182.15M-$4.13N/AN/AN/AN/A-34.65%-32.76%N/ARNAAvidity Biosciences-$322.30M-$3.56N/AN/AN/A-4,247.77%-33.45%-30.22%11/6/2025 (Estimated)RVMDRevolution Medicines-$600.09M-$4.50N/AN/AN/AN/A-41.78%-35.63%11/5/2025 (Estimated)RYTMRhythm Pharmaceuticals-$260.60M-$3.01N/AN/AN/A-117.13%-1,831.43%-48.33%11/4/2025 (Estimated)Latest APGE, RVMD, RYTM, and RNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025APGEApogee Therapeutics-$1.03-$1.13-$0.10-$1.13N/AN/A8/6/2025Q2 2025RVMDRevolution Medicines-$0.94-$1.31-$0.37-$1.31$0.50 millionN/A8/5/2025Q2 2025RYTMRhythm Pharmaceuticals-$0.66-$0.75-$0.09-$0.75$43.72 million$48.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPGEApogee TherapeuticsN/AN/AN/AN/AN/ARNAAvidity BiosciencesN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGEApogee TherapeuticsN/A16.3616.36RNAAvidity BiosciencesN/A9.269.26RVMDRevolution Medicines0.1311.7911.79RYTMRhythm PharmaceuticalsN/A2.792.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGEApogee Therapeutics79.04%RNAAvidity BiosciencesN/ARVMDRevolution Medicines94.34%RYTMRhythm PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipAPGEApogee Therapeutics42.77%RNAAvidity Biosciences3.83%RVMDRevolution Medicines8.20%RYTMRhythm Pharmaceuticals6.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGEApogee Therapeutics9146.11 million26.39 millionOptionableRNAAvidity Biosciences190128.65 million123.73 millionOptionableRVMDRevolution Medicines250186.93 million171.60 millionOptionableRYTMRhythm Pharmaceuticals14066.42 million62.37 millionOptionableAPGE, RVMD, RYTM, and RNA HeadlinesRecent News About These CompaniesFDA Priority Review for Setmelanotide in Hypothalamic Obesity Might Change The Case For Investing In Rhythm Pharmaceuticals (RYTM)August 21 at 9:09 AM | finance.yahoo.comRhythm Pharma label expansion requests for obesity drug undergo U.S. EU reviewsAugust 21 at 9:09 AM | msn.comRhythm Pharmaceuticals announces FDA acceptance of sNDA for setmelanotideAugust 20 at 10:59 PM | msn.comRhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic ObesityAugust 20 at 4:01 PM | globenewswire.comLord Abbett & CO. LLC Has $7.17 Million Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)August 19 at 5:17 AM | marketbeat.comPNC Financial Services Group Inc. Boosts Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)August 18 at 3:16 AM | marketbeat.comFox Run Management L.L.C. Makes New Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)August 17, 2025 | marketbeat.comE Fund Management Co. Ltd. Makes New $286,000 Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)August 17, 2025 | marketbeat.comInsider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Sells 1,500 Shares of StockAugust 16, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CFO Sells $333,792.00 in StockAugust 16, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CFO Hunter C. Smith Sells 24,611 SharesAugust 16, 2025 | marketbeat.com5,502 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Acquired by Entropy Technologies LPAugust 16, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Increases Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)August 16, 2025 | marketbeat.comJoseph Shulman Sells 3,984 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) StockAugust 15, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Joseph Shulman Sells 3,984 SharesAugust 14, 2025 | insidertrades.comInformed Momentum Co LLC Sells 17,970 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)August 14, 2025 | marketbeat.com7,701 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Purchased by Aigen Investment Management LPAugust 14, 2025 | marketbeat.comRhythm Pharmaceuticals’ RM-718 Study: A Potential Game-Changer in Obesity TreatmentAugust 14, 2025 | msn.comRhythm Pharmaceuticals (NASDAQ:RYTM) Sets New 1-Year High - What's Next?August 13, 2025 | marketbeat.comPersistent Asset Partners Ltd Sells 6,811 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)August 13, 2025 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), Krystal Biotech (KRYS)August 13, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPGE, RVMD, RYTM, and RNA Company DescriptionsApogee Therapeutics NASDAQ:APGE$36.35 +0.33 (+0.92%) Closing price 04:00 PM EasternExtended Trading$36.42 +0.07 (+0.19%) As of 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Avidity Biosciences NASDAQ:RNA$44.66 +0.32 (+0.72%) Closing price 04:00 PM EasternExtended Trading$44.88 +0.22 (+0.48%) As of 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.Revolution Medicines NASDAQ:RVMD$36.48 +0.32 (+0.88%) Closing price 04:00 PM EasternExtended Trading$36.35 -0.13 (-0.34%) As of 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Rhythm Pharmaceuticals NASDAQ:RYTM$101.68 +2.98 (+3.02%) Closing price 04:00 PM EasternExtended Trading$99.21 -2.47 (-2.43%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Palantir is Selling Off, BigBear.ai Could Be Your Hedge ASML Has Entered Buy Territory, But Only For Patient Investors Lowe’s Builds Value for Investors: Still a Good Buy in 2025 Target: Missing the Mark in 2025—Downtrend May Continue Toll Brothers: A Great Buy and Hold Stock With Risks in 2025 Amazon Stock Sets Up for Breakout After Bullish Crossover Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access